{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:48:49Z","timestamp":1792428529637,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11255-020-02623-7","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T16:03:38Z","timestamp":1598889818000},"page":"301-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Irem","family":"Bilgetekin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Erturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Bugdayci","family":"Basal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7310-9328","authenticated-orcid":false,"given":"Cengiz","family":"Karacin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuri","family":"Karadurmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berna","family":"Oksuzoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"2623_CR1","doi-asserted-by":"publisher","first-page":"760","DOI":"10.4103\/2230-8210.141320","volume":"18","author":"M Sahay","year":"2014","unstructured":"Sahay M, Sahay R (2014) Hyponatremia: a practical approach. Indian J Endocrinol Metab 18:760\u2013771","journal-title":"Indian J Endocrinol Metab"},{"key":"2623_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.critrevonc.2016.03.010","volume":"102","author":"R Berardi","year":"2016","unstructured":"Berardi R, Rinaldi S, Caramanti M, Grohe C, Santoni M, Morgese F, Torniai M, Savini A, Fiordoliva I, Cascinu S (2016) Hyponatremia in cancer patients: time for a new approach. Crit Rev Oncol Hematol 102:15\u201325","journal-title":"Crit Rev Oncol Hematol"},{"key":"2623_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CMAR.S90169","volume":"8","author":"B Thajudeen","year":"2016","unstructured":"Thajudeen B, Salahudeen AK (2016) Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives. Cancer Manag Res 8:105\u2013114","journal-title":"Cancer Manag Res"},{"key":"2623_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S1043-2760(03)00048-1","volume":"14","author":"BF Palmer","year":"2003","unstructured":"Palmer BF (2003) Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol Metab 14:182\u2013187","journal-title":"Trends Endocrinol Metab"},{"key":"2623_CR5","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.lfs.2004.11.010","volume":"76","author":"J Kojima","year":"2005","unstructured":"Kojima J, Katayama Y, Moro N, Kawai H, Yoneko M, Mori T (2005) Cerebral salt wasting in subarachnoid hemorrhage rats: model, mechanism, and tool. Life Sci 76:2361\u20132370","journal-title":"Life Sci"},{"key":"2623_CR6","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1365-2265.2006.02583.x","volume":"65","author":"G Gill","year":"2006","unstructured":"Gill G, Huda B, Boyd A, Skagen K, Wile D, Watson I, van Heyningen C (2006) Characteristics and mortality of severe hyponatraemia\u2014a hospital-based study. Clin Endocrinol (Oxf) 65:246\u2013249","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2623_CR7","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1681\/ASN.2007070752","volume":"19","author":"AM Shea","year":"2008","unstructured":"Shea AM, Hammill BG, Curtis LH, Szczech LA, Schulman KA (2008) Medical costs of abnormal serum sodium levels. J Am Soc Nephrol 19:764\u2013770","journal-title":"J Am Soc Nephrol"},{"key":"2623_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00380-017-1067-3","volume":"33","author":"S Kiuchi","year":"2018","unstructured":"Kiuchi S, Hisatake S, Kabuki T, Oka T, Dobashi S, Fujii T, Ikeda T (2018) The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients. Heart Vessels 33:367\u2013373","journal-title":"Heart Vessels"},{"issue":"Suppl 2","key":"2623_CR9","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/ndt\/gfu040","volume":"29","author":"G Spasovski","year":"2014","unstructured":"Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, Van Biesen W, Nagler E (2014) Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant 29(Suppl 2):i1\u2013i39","journal-title":"Nephrol Dial Transplant"},{"key":"2623_CR10","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355:2099\u20132112","journal-title":"N Engl J Med"},{"key":"2623_CR11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1681\/ASN.2009080857","volume":"21","author":"T Berl","year":"2010","unstructured":"Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS, Investigators S (2010) Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 21:705\u2013712","journal-title":"J Am Soc Nephrol"},{"key":"2623_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"2623_CR13","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.cardfail.2016.06.177","volume":"22","author":"DP Lubeck","year":"2016","unstructured":"Lubeck DP, Duryea J, Danese M, Krasa H, Chido J (2016) Treatment length of stay for chronic heart failure patients in a hyponatremia registry patients in a hyponatremia registry. J Cardiac Fail 22:S59","journal-title":"J Cardiac Fail"},{"key":"2623_CR14","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/cam4.805","volume":"6","author":"RJ Gralla","year":"2017","unstructured":"Gralla RJ, Ahmad F, Blais JD, Chiodo J 3rd, Zhou W, Glaser LA, Czerwiec FS (2017) Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials. Cancer Med 6:723\u2013729","journal-title":"Cancer Med"},{"key":"2623_CR15","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/cncr.28468","volume":"120","author":"AK Salahudeen","year":"2014","unstructured":"Salahudeen AK, Ali N, George M, Lahoti A, Palla S (2014) Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety. Cancer 120:744\u2013751","journal-title":"Cancer"},{"key":"2623_CR16","doi-asserted-by":"publisher","first-page":"23871","DOI":"10.18632\/oncotarget.13372","volume":"8","author":"R Berardi","year":"2017","unstructured":"Berardi R, Santoni M, Newsom-Davis T, Caramanti M, Rinaldi S, Tiberi M, Morgese F, Torniai M, Pistelli M, Onofri A, Bower M, Cascinu S (2017) Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. Oncotarget 8:23871\u201323879","journal-title":"Oncotarget"},{"key":"2623_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.lungcan.2009.05.015","volume":"68","author":"O Hansen","year":"2010","unstructured":"Hansen O, Sorensen P, Hansen KH (2010) The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer 68:111\u2013114","journal-title":"Lung Cancer"},{"key":"2623_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1055\/s-0030-1256668","volume":"65","author":"C Petereit","year":"2011","unstructured":"Petereit C, Zaba O, Teber I, Grohe C (2011) Is hyponatremia a prognostic marker of survival for lung cancer? Pneumologie 65:565\u2013571","journal-title":"Pneumologie"},{"key":"2623_CR19","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s12885-016-2610-9","volume":"16","author":"JJ Castillo","year":"2016","unstructured":"Castillo JJ, Glezerman IG, Boklage SH, Chiodo J 3rd, Tidwell BA, Lamerato LE, Schulman KL (2016) The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. BMC Cancer 16:564\u2013564","journal-title":"BMC Cancer"},{"key":"2623_CR20","doi-asserted-by":"publisher","first-page":"e0124105","DOI":"10.1371\/journal.pone.0124105","volume":"10","author":"G Corona","year":"2015","unstructured":"Corona G, Giuliani C, Verbalis JG, Forti G, Maggi M, Peri A (2015) Hyponatremia improvement is associated with a reduced risk of mortality: evidence from a meta-analysis. PLoS ONE 10:e0124105\u2013e0124105","journal-title":"PLoS ONE"},{"key":"2623_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1634\/theoncologist.2011-0400","volume":"17","author":"JJ Castillo","year":"2012","unstructured":"Castillo JJ, Vincent M, Justice E (2012) Diagnosis and management of hyponatremia in cancer patients. Oncologist 17:756","journal-title":"Oncologist"},{"key":"2623_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1053\/j.ackd.2013.05.005","volume":"21","author":"MH Rosner","year":"2014","unstructured":"Rosner MH, Dalkin AC (2014) Electrolyte disorders associated with cancer. Adv Chronic Kidney Dis 21:7\u201317","journal-title":"Adv Chronic Kidney Dis"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02623-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-020-02623-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02623-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:21:53Z","timestamp":1630369313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-020-02623-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["2623"],"URL":"https:\/\/doi.org\/10.1007\/s11255-020-02623-7","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"30 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no confict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was approved by the local ethical committee of the University of Health Sciences, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital (TUEK meeting number: 85-31.12.2019) in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}